TU-G-BRB-00: Clinical Trials in Proton and Particle Therapy

2015 ◽  
Vol 42 (6Part35) ◽  
pp. 3629-3629
Author(s):  
Reinhard Schulte
Keyword(s):  
Clinical Trials ◽  
Particle Therapy

Particle Therapy Clinical Trials

2018 ◽  
pp. 181-192
Author(s):  
Cai Grau ◽  
Damien Charles Weber ◽  
Johannes A. Langendijk ◽  
James D. Cox ◽  
Tadashi Kamada ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Particle Therapy

scholarly journals A 20-Year Analysis of Clinical Trials Involving Proton Beam Therapy

2016 ◽  
Vol 3 (3) ◽  
pp. 398-406 ◽  
Author(s):  
Bismarck C. L. Odei ◽  
Dustin Boothe ◽  
Sameer R. Keole ◽  
Carlos E. Vargas ◽  
Robert L. Foote ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Clinical Trials ◽  
Nervous System ◽  
Proton Beam ◽  
Phase Ii ◽  
Proton Beam Therapy ◽  
Primary Treatment ◽  
Particle Therapy ◽  
Phase Iii ◽  
Phase Ii Trials

Purpose: Clinical trials (CTs) in proton beam therapy (PBT) are important for determining its benefits relative to other treatments. An analysis of PBT trials is, thus, warranted to understand the current state of PBT CTs and the factors affecting current and future trials. Materials and Methods: We queried the clinicaltrials.gov Website using the search terms: proton beam therapy, proton radiation, and protons. A total of 152 PBT CTs were identified. We used χ2 analysis and logistic regression to evaluate trial characteristics. Results: Most CTs were recruiting (n = 79; 52.0%), phase II (n = 95; 62.5%), open label (n = 134; 88.2%), single-group assignment (n = 84; 55.3%), and with primary treatment endpoints of safety and efficacy (n = 94; 61.8%). The primary treatment sites included gastrointestinal (n = 32; 21.1%), central nervous system (n = 31; 20.4%), lung (n = 21; 13.8%), prostate (n = 19; 12.5%), sarcoma (n = 15; 9.9%), and others (n = 24; 15.8%). Comparison studies between radiation modalities involved PBT and intensity-modulated photon therapy (n = 11; 7.2%), PBT and general photon therapy (n = 8; 5.3%), and PBT and carbon-ion therapy (n = 7; 4.6%). The PBT CTs underwent substantial growth after 2008 but now appear to be in decline. Nongovernmental institutions, comprising university centers, hospital systems, and research groups, have funded the greatest number of CTs (n= 106; 69.7%). The National Institutes of Health (NIH) were more likely to fund CTs involving the central nervous system ( P = 0.02). Trials involving NIH funding were more likely to result in successful trial completion ( P = 0.02). Conclusion: Among PBT CTs, most were phase II trials, with a very few being phase III CTs. Funding of PBT CTs originating from industry or the NIH is limited. Recently, there has been a declining trajectory of newly initiated PBT trials. It is not yet clear whether this represents a true trend or just a pause in CT implementation. Despite multiple impediments to PBT CTs, the particle therapy community continues to work toward evidence generation.

scholarly journals Ongoing and future clinical trials in particle therapy in the Nordic countries

2020 ◽  
Vol 59 (10) ◽  
pp. 1145-1150 ◽  
Author(s):  
Petra Witt Nyström ◽  
Åse Bratland ◽  
Heikki Minn ◽  
Cai Grau
Keyword(s):  
Clinical Trials ◽  
Nordic Countries ◽  
Particle Therapy

scholarly journals Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications

Pharmaceutics ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 49
Author(s):  
Bryce Nelson ◽  
Jan Andersson ◽  
Frank Wuest
Keyword(s):  
Clinical Trials ◽  
Particle Therapy ◽  
Particle Emissions ◽  
Targeted Alpha Therapy ◽  
Radionuclide Production ◽  
Decay Properties ◽  
Superior Efficacy ◽  
The Future ◽  
Production Techniques ◽  
Alpha Therapy

This review outlines the accomplishments and potential developments of targeted alpha (α) particle therapy (TAT). It discusses the therapeutic advantages of the short and highly ionizing path of α-particle emissions; the ability of TAT to complement and provide superior efficacy over existing forms of radiotherapy; the physical decay properties and radiochemistry of common α-emitters, including 225Ac, 213Bi, 224Ra, 212Pb, 227Th, 223Ra, 211At, and 149Tb; the production techniques and proper handling of α-emitters in a radiopharmacy; recent preclinical developments; ongoing and completed clinical trials; and an outlook on the future of TAT.

scholarly journals Prospective data registration and clinical trials for particle therapy in Europe

2018 ◽  
Vol 128 (1) ◽  
pp. 9-13 ◽  
Author(s):  
Johannes A. Langendijk ◽  
Roberto Orecchia ◽  
Karin Haustermans ◽  
Daniel Zips ◽  
Jacques Balosso ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Particle Therapy ◽  
Prospective Data ◽  
Data Registration

Localization of Gallium-67 in Peritoneal Cells by Electron Microscopic Autoradiography

1973 ◽  
Vol 31 ◽  
pp. 404-405
Author(s):  
D. C. Swartzendruber ◽  
Norma L. Idoyaga-Vargas
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Tumor Tissue ◽  
Soft Tissue Tumors ◽  
Clinical Usefulness ◽  
Electron Microscopic ◽  
Normal Cells ◽  
Electron Microscopic Autoradiography ◽  
Peritoneal Cells ◽  
Gallium 67

The radionuclide gallium-67 (67Ga) localizes preferentially but not specifically in many human and experimental soft-tissue tumors. Because of this localization, 67Ga is used in clinical trials to detect humar. cancers by external scintiscanning methods. However, the fact that 67Ga does not localize specifically in tumors requires for its eventual clinical usefulness a fuller understanding of the mechanisms that control its deposition in both malignant and normal cells. We have previously reported that 67Ga localizes in lysosomal-like bodies, notably, although not exclusively, in macrophages of the spocytaneous AKR thymoma. Further studies on the uptake of 67Ga by macrophages are needed to determine whether there are factors related to malignancy that might alter the localization of 67Ga in these cells and thus provide clues to discovering the mechanism of 67Ga localization in tumor tissue.

Sign in / Sign up

Export Citation Format

Share Document